Press Releases

July 11, 2012

Edison “Ed” Liu, MD, was unanimously elected to the Foundation for the National Institutes of Health (FNIH) Board of Directors. He began his term June 19, 2012.

July 11, 2012

Joel S. Marcus was unanimously elected to the Foundation for the National Institutes of Health (FNIH) Board of Directors. He began his term May 16, 2012.

July 11, 2012

Steven C. Mayer was unanimously elected to the Foundation for the National Institutes of Health (FNIH) Board of Directors. He began his term May 16, 2012.

July 11, 2012

Garry A. Neil, MD was unanimously elected to the Foundation for the National Institutes of Health (FNIH) Board of Directors. He began his term May 16, 2012.

July 11, 2012

Nina K. Solarz was unanimously elected to the Foundation for the National Institutes of Health (FNIH) Board of Directors. She began her term May 16, 2012.

July 2, 2012

The U.S.-Russia Collaboration in the Biomedical Sciences announces a new Visiting Fellows Program at the National Institutes of Health (NIH). The program invites applications from Russian researchers to spend two years in the laboratories within the NIH Intramural Research Program (IRP).

June 20, 2012

Bethesda, MD (June 20, 2012) — The Foundation for the National Institutes of Health (FNIH), along with the NIH Fogarty International Center (FIC), is contributing to research focused on the discovery of novel dietary and microbial therapeutics that will benefit infants and children living in countries with widespread malnutrition and at risk for disease and growth deficits.

June 6, 2012

The Foundation for the National Institutes of Health (FNIH) is accepting nominations for the first Lurie Prize in the Biomedical Sciences, an annual award recognizing outstanding achievement by a young scientist in biomedical research.

June 1, 2012

The Food and Drug Administration (FDA) has drafted a regulatory guidance describing a new way of conducting breast cancer drug trials that promises to reduce substantially the time and cost of getting new treatments to patients. The approach is based on a trial design being tested in the I-SPY 2 TRIAL, an innovative Phase II breast cancer trial being conducted under the auspices of the Biomarkers Consortium, a public-private partnership led by the Foundation for the National Institutes of Health (FNIH) that includes representatives from NIH, FDA, and multiple pharmaceutical companies and academic research centers.

May 18, 2012

The Foundation for the National Institutes of Health (FNIH) announces that Burlington Coat Factory has donated $25,000 in support of The Heart Truth® Campaign.